CLINICAL TRIALS PROFILE FOR DEGARELIX ACETATE
✉ Email this page to a colleague
All Clinical Trials for degarelix acetate
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00215683 ↗ | An Extension Study Evaluating the Long-Term Safety and Tolerability of Degarelix One-Month Depots in Prostate Cancer | Completed | Ferring Pharmaceuticals | Phase 2/Phase 3 | 2005-02-01 | This was an extension study for the study FE200486 CS12 (NCT00819156). Each participant was to be treated until he was discontinued or withdrawn from the study, or a marketing authorization for degarelix had been obtained. The study was terminated when all ongoing participants had been treated for at least 5 years (including one year in the main study). |
| NCT00946920 ↗ | A Trial of Degarelix in Patients With Prostate Cancer | Completed | Ferring Pharmaceuticals | Phase 3 | 2009-06-01 | A phase 3, open-label, parallel group, one year trial comparing the efficacy and safety of degarelix 3-month depot with the established therapy goserelin acetate 3-month implant in patients with prostate cancer. |
| NCT01220869 ↗ | A Study of Degarelix in Taiwanese Patients With Prostate Cancer | Completed | Ferring Pharmaceuticals | Phase 3 | 2010-12-01 | A phase III trial investigating the efficacy and safety of degarelix one-month depot in Taiwanese patients with prostate cancer. |
| NCT01242748 ↗ | A Degarelix Trial in Patients With Prostate Cancer | Terminated | Ferring Pharmaceuticals | Phase 3 | 2010-10-01 | A phase III extension trial comparing the efficacy and safety of degarelix 3 month depot with the established therapy Zoladex 3 month implant in patients with prostate cancer. |
| NCT01309672 ↗ | S1014 Abiraterone Acetate in Treating Patients With Prostate Cancer Who Have Undergone Initial Hormone Therapy | Active, not recruiting | National Cancer Institute (NCI) | Phase 2 | 2011-08-09 | RATIONALE: Androgens can cause the growth of prostate cancer cells. Antiandrogen drugs, such as abiraterone acetate, may lessen the amount of androgens made by the body. It may also stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying the side effects and how well abiraterone acetate works in treating patients with prostate cancer who have undergone initial hormone therapy. |
| NCT01309672 ↗ | S1014 Abiraterone Acetate in Treating Patients With Prostate Cancer Who Have Undergone Initial Hormone Therapy | Active, not recruiting | Southwest Oncology Group | Phase 2 | 2011-08-09 | RATIONALE: Androgens can cause the growth of prostate cancer cells. Antiandrogen drugs, such as abiraterone acetate, may lessen the amount of androgens made by the body. It may also stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying the side effects and how well abiraterone acetate works in treating patients with prostate cancer who have undergone initial hormone therapy. |
| NCT01344564 ↗ | Initiation of Androgen Deprivation Therapy for Prostate Cancer Using Degarelix Followed by Leuprolide | Completed | Ferring Pharmaceuticals | N/A | 2011-04-01 | The purpose of this study is to determine if patients initiating androgen deprivation therapy (ADT) for prostate cancer can be transitioned from degarelix acetate to leuprolide acetate after an initial three-month period without a rise in serum testosterone. The investigators expect testosterone will quickly and reliably reach castrate levels after initiation of ADT and will remain castrate during the transition, and there will be no "testosterone surge" after leuprolide injection. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for degarelix acetate
Condition Name
Clinical Trial Locations for degarelix acetate
Trials by Country
Clinical Trial Progress for degarelix acetate
Clinical Trial Phase
Clinical Trial Sponsors for degarelix acetate
Sponsor Name
